1. Home
  2. Live Updates
  3. Dupilumab development programdupilumab

Page 8 - Dupilumab Development Programdupilumab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dupilumab development programdupilumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dupilumab Development Programdupilumab Today - Breaking & Trending Today

PRIME, PRIME 2 Data Show 12-, 24-Week Improvements in Patients With Prurigo Nodularis

The LIBERTY-PN PRIME and PRIME2 trials investigated itch response to dupilumab among patients who have prurigo nodularis.
....

Worst Itch Numeric Rating Scale , Investigator Global Assessment , Dermatology Life Quality Index , Prurigo Nodularis , Wi Nrs , Iga Pn S ,

Combo Therapy Relieves Delayed Rash Symptoms in AD Following mRNA Vaccine

In a case report, dupilumab and prednisone were among the treatments for atopic dermatitis (AD) used to relieve a patient of her delayed generalized hypersensitivity reaction to the mRNA COVID-19 vaccine. ....

Atopic Dermatitis , Lyme Serology ,

Sanofi - Aventis Groupe: Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic ....

France General , United States , Eva Schaefer Jansen , Sandrine Guendoul , Surya Bhatt , Gewinn Nur , Tarik Elgoutni , Sally Bain , Vesna Tosic , Felix Lauscher , Sharon Chen , Nathalie Pham , American Thoracic Society , Regeneron Pharmaceuticals Inc , Trial Program , International Conference , Clinical Research Program , Exchange Commission , Regeneron Genetics Center , Pulmonary Research , Dupilumab Development Program , New England Journal , Thoracic Society , England Journal , Recently Published Pulmonary , Clinical Trial Results ,

Phase 3 Study Finds Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation

In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung function, and improved quality of life compared with patients given a placebo. ....

United States , American Thoracic Society International Conference , New England Journal , Thoracic Society International Conference , Respiratory Questionnaire , Evaluating Respiratory Symptoms , Wats 2023 , American Thoracic Society Conference News ,

Treatment Improves Outcomes in Patients With CRSwNP, Features of Obstructive Lung Disease

In the phase 3 SINUS-24 and SINUS-52 trials, dupilumab improved clinical outcomes and and health-related quality of life among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease. ....

University Of Pennsylvania Smell Identification Test , Pennsylvania Smell Identification Test , Sino Nasal Outcome Test , Sinus 24 , Sinus 52 , Obstructive Lung Disease , Type 2 Inflammation ,